Trial Profile
A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 15 May 2018 Status changed from recruiting to active, no longer recruiting.
- 08 May 2017 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.